Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas: Complete Statistical AnalysisIndependent statistical analysis of Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NADIMIndependent statistical analysis of the NADIM II phase 2 randomized trial evaluating neo-adjuvant immunotherapy with nivolumab plus chemotherapy in non small cell lung cancer.
- NALAIndependent statistical analysis of NALA, a randomized phase 3 trial of neratinib plus capecitabine versus lapatinib plus capecitabine in HER2+ metastatic breast cancer after two or more prior HER2-directed regimens.
- Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NARLALIndependent statistical analysis of Navelbine And Radiotherapy in Locally Advanced Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00887783).
- NATALEEA detailed statistical analysis of the phase 3 NATALEE trial evaluating ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer, including trial design, endpoint methodology, statistical interpretation,…
- National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC: Complete Statistical AnalysisIndependent statistical analysis of National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I – II Trial: Complete Statistical AnalysisIndependent statistical analysis of Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- NAVIGATEAn educational statistical analysis of the phase 2 NAVIGATE trial of larotrectinib in adults and children with NTRK-fusion positive solid tumors, covering its nonrandomized multi-arm design, response endpoint, statistical methodology, and interpretation.
- NCCTG N9831Independent statistical analysis of NCCTG N9831, a randomized phase 3 trial evaluating doxorubicin, cyclophosphamide, and paclitaxel with or without trastuzumab in women with HER2-positive node-positive or high-risk node-negative breast cancer.
- Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy: Complete Statistical AnalysisIndependent statistical analysis of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Neo ALTTOIndependent statistical analysis of Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00553358).
- Neo TrioIndependent statistical analysis of Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Neo-AEGISIndependent statistical analysis of the Neo-AEGIS phase 3 randomized trial evaluating perioperative chemotherapy versus chemoradiotherapy approaches in oesophageal and oesophago-gastric junction adenocarcinoma.
- Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients: Complete Statistical AnalysisIndependent statistical analysis of Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04512430).
- Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03747120).
- Neoadjuvant Immunotherapy in Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Immunotherapy in Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04434560).
- Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04869137).
- Neoadjuvant Pazopanib in Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Pazopanib in Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01361113).
- Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2: primary endpoint results, effect estimate…
- Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00828308).
- NeoALTTOIndependent statistical analysis of the phase 3 NeoALTTO trial of lapatinib and trastuzumab in neoplasms of the breast, including pathological complete response, event-free survival, overall survival, landmark analyses, methodology, and interpretation.
- NeohttpIndependent statistical analysis of Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02345772).
- NEOMUNIndependent statistical analysis of Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03197467).
- NEON-1Independent statistical analysis of NEON-1, a phase 1 study of ALPN-202 in subjects with advanced malignancies, including trial design, endpoints, statistical methodology, and interpretation.
- NEST-1Independent statistical analysis of Combination Immunotherapy in Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05571293).
- NETTER-1Independent statistical analysis of the phase 3 NETTER-1 trial comparing 177Lu-DOTA0-Tyr3-Octreotate with Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours.
- Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain: Complete Statistical AnalysisIndependent statistical analysis of Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- NIAGARAIndependent statistical analysis of Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NICHEIndependent statistical analysis of NICHE (NCT03026140), a randomized phase 2 trial evaluating neoadjuvant immune checkpoint inhibition and novel immuno-oncology combinations in early-stage colon cancer.
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- NIMBUSIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple…
- Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02389764).
- Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NIRAFIndependent statistical analysis of Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Niraparib + Dostarlimab + RT in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab + RT in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04409002).
- Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04584255).
- NIRVANA-1Independent statistical analysis of the randomized phase 2 NIRVANA-1 trial evaluating niraparib with bevacizumab after complete cytoreduction in patients with ovarian cancer, including its progression-free survival endpoint and planned statistical interpretation.
- Nitrous Oxide for Identifying the Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial: Complete Statistical AnalysisIndependent statistical analysis of Nitrous Oxide for Identifying the Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…